Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
William Hill price target lowered to 272 GBp from 300 GBp at RBC Capital » 12:59
10/27/20
10/27
12:59
10/27/20
12:59
WIMHY

William Hill

$0.00 /

+ (+0.00%)

RBC Capital analyst…

RBC Capital analyst Christine Zhou lowered the firm's price target on William Hill to 272 GBp from 300 GBp and keeps a Sector Perform rating on the shares.

ShowHide Related Items >><<
WIMHY William Hill
$0.00 /

+ (+0.00%)

WIMHY William Hill
$0.00 /

+ (+0.00%)

10/05/20 JPMorgan
Caesars price target raised to $67 from $63 at JPMorgan
10/02/20
Fly Intel: Top five analyst downgrades
10/02/20 Berenberg
Berenberg downgrades William Hill, expects bid to be accepted
10/02/20 Berenberg
William Hill downgraded to Hold from Buy at Berenberg
WIMHY William Hill
$0.00 /

+ (+0.00%)

WIMHY William Hill
$0.00 /

+ (+0.00%)

Hot Stocks
Intrado to divest Health Advocate business for $690M to Teleperformance » 12:47
10/27/20
10/27
12:47
10/27/20
12:47
APO

Apollo Global

$40.03 /

-0.08 (-0.20%)

Intrado announced it has…

Intrado announced it has entered into a definitive agreement with Teleperformance, a global group in digitally integrated business services, for the sale of Intrado's Health Advocate business for the purchase price of $690M. "After a strategic review of our businesses, we made the decision to sell Health Advocate to allow greater focus on Intrado's other cloud businesses," said John Shlonsky, President and CEO of Intrado. "Teleperformance will be an outstanding home for Health Advocate. Teleperformance's focus on personalized customer experience and innovation aligns closely with Health Advocate's nearly identical priorities. We are excited for the Health Advocate team to be able to continue to expand the business within the world-class Teleperformance organization." The transaction is expected to close in the first quarter of 2021, subject to regulatory approvals and other customary closing conditions. Intrado is controlled by affiliates of certain funds managed by Apollo Global Management.

ShowHide Related Items >><<
APO Apollo Global
$40.03 /

-0.08 (-0.20%)

APO Apollo Global
$40.03 /

-0.08 (-0.20%)

10/26/20 Evercore ISI
Apollo Global upgraded to Outperform from In Line at Evercore ISI
09/28/20 Roth Capital
Roth Capital sees currently uncaptured value for both Caesars, William Hill
07/01/20 Barclays
Apollo Global price target raised to $51 from $44 at Barclays
06/30/20
Fly Intel: Top five analyst downgrades
APO Apollo Global
$40.03 /

-0.08 (-0.20%)

  • 26
    Nov
APO Apollo Global
$40.03 /

-0.08 (-0.20%)

APO Apollo Global
$40.03 /

-0.08 (-0.20%)

APO Apollo Global
$40.03 /

-0.08 (-0.20%)

Conference/Events
JPMorgan gaming analyst to hold an analyst/industry conference call » 09:40
10/27/20
10/27
09:40
10/27/20
09:40
WIMHY

William Hill

$0.00 /

+ (+0.00%)

, CZR

Caesars

$51.75 /

+ (+0.00%)

US Gaming & Lodging…

US Gaming & Lodging Analyst Politzer and EMEA Special Situations Analyst Dunlop discuss Caesars Entertainment and William Hill signing their first NFL team sponsorship, becoming a sports betting partner of the Indianapolis Colts on an Analyst/Industry conference call to be held on October 27 at 10 am.

ShowHide Related Items >><<
WIMHY William Hill
$0.00 /

+ (+0.00%)

CZR Caesars
$51.75 /

+ (+0.00%)

WIMHY William Hill
$0.00 /

+ (+0.00%)

10/05/20 JPMorgan
Caesars price target raised to $67 from $63 at JPMorgan
10/02/20
Fly Intel: Top five analyst downgrades
10/02/20 Berenberg
Berenberg downgrades William Hill, expects bid to be accepted
10/02/20 Berenberg
William Hill downgraded to Hold from Buy at Berenberg
CZR Caesars
$51.75 /

+ (+0.00%)

10/16/20 Morgan Stanley
Caesars price target raised to $68 from $54 at Morgan Stanley
10/08/20 Truist
DraftKings price target raised to $60 from $39 at Truist
10/05/20 Union Gaming
Caesars price target raised to $100 from $60 at Union Gaming
CZR Caesars
$51.75 /

+ (+0.00%)

  • 29
    Sep
WIMHY William Hill
$0.00 /

+ (+0.00%)

WIMHY William Hill
$0.00 /

+ (+0.00%)

CZR Caesars
$51.75 /

+ (+0.00%)

CZR Caesars
$51.75 /

+ (+0.00%)

Hot Stocks
Novavax expects interim data from Phase 3 COVID-19 trial as soon as 1Q21 » 09:05
10/27/20
10/27
09:05
10/27/20
09:05
NVAX

Novavax

$87.34 /

-5.74 (-6.17%)

Novavax announced updates…

Novavax announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX-CoV2373 is a stable, prefusion protein made using Novavax' nanoparticle technology and includes Novavax' proprietary Matrix-M adjuvant. The Company also announced that it will present data from its ongoing Phase 1/2 clinical trial, including new Phase 2 reactogenicity data, on Friday, October 30 during the United States Center for Disease Control and Prevention's Advisory Committee on Immunization Practices' meeting. Novavax has enrolled over 5,500 participants to date in the United Kingdom trial, which it has expanded to 15,000 volunteers. The increased enrollment is likely to facilitate assessment of safety and efficacy in a shorter time period. Novavax expects this trial to be fully enrolled by the end of November, and dependent on the overall COVID-19 attack rate, interim data in this event-driven trial are expected as soon as early first quarter 2021. These data are expected to serve as the basis for global licensure. Novavax currently expects the pivotal clinical trial to begin in the United States and Mexico by the end of November. The Company has made significant progress in large-scale manufacturing, with delays experienced versus original timing estimates. Novavax has been developing large-scale manufacturing processes at multiple sites around the world and plans to use production from its contract manufacturing site at FUJIFILM Diosynth Biotechnologies' Morrisville, North Carolina site in this Phase 3 clinical trial. Novavax' first pivotal Phase 3 clinical trial, begun in September in partnership with the U.K. Government's Vaccines Taskforce, will be expanded from 10,000 to 15,000 volunteers, some of whom have been recruited through the National Health Service Vaccine Registry. The trial protocol calls for unblinding of data once 152 participants have achieved mild, moderate or severe endpoints. Two interim analyses are planned once 66 and 110 endpoints have occurred. Novavax' pivotal Phase 3 clinical trial is being conducted with support from the U.S. Government through Operation Warp Speed. The trial design is harmonized with those of other leading companies, and calls for the enrollment of up to 30,000 participants in the U.S. and Mexico, with proportional representation among diverse populations most vulnerable to COVID-19 distributed across race/ethnicity, age and those living with co-morbidities. The trial protocol will be posted on Novavax' website upon initiation.

ShowHide Related Items >><<
NVAX Novavax
$87.34 /

-5.74 (-6.17%)

NVAX Novavax
$87.34 /

-5.74 (-6.17%)

10/22/20 B. Riley Securities
Novavax price target lowered to $223 from $257 at B. Riley Securities
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/25/20 Raymond James
Endo deal could generate $50M-$75M in cash inflow, says Raymond James
09/15/20 B. Riley Securities
Novavax deal with SIIPL doubles manufacturing capacity, says B. Riley FBR
NVAX Novavax
$87.34 /

-5.74 (-6.17%)

NVAX Novavax
$87.34 /

-5.74 (-6.17%)

NVAX Novavax
$87.34 /

-5.74 (-6.17%)

NVAX Novavax
$87.34 /

-5.74 (-6.17%)

Hot Stocks
DraftKings extends sports betting agreement with MansionBet » 06:10
10/27/20
10/27
06:10
10/27/20
06:10
DKNG

DraftKings

$39.67 /

-3.05 (-7.14%)

DraftKings announced the…

DraftKings announced the renewal and extension of its relationship with MansionBet, the Gibraltar based sport betting brand of the Mansion Group, a leading provider of online gaming, with a portfolio of well-known online casino brands, as well as a sportsbook. The long-term agreement will see DraftKings' B2B technology continue to power the tier one operator's sportsbook and casino platform, in addition to providing a suite of managed services covering compliance, payments and anti-fraud protocols. Having experienced significant growth since launching in 2018, MansionBet will now leverage DraftKings' suite of APIs across their entire sportsbook. The expansion will significantly enhance MansionBet's customer offerings and experience, particularly for horse racing, which will now feature additional streaming coverage and Timeform content from both U.K. and international tracks.

ShowHide Related Items >><<
DKNG DraftKings
$39.67 /

-3.05 (-7.14%)

DKNG DraftKings
$39.67 /

-3.05 (-7.14%)

10/15/20 Craig-Hallum
Strong results in NJ to encourage states to legalize iGaming, says Craig-Hallum
10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Benchmark
DraftKings price target raised to $60 from $57 at Benchmark
10/12/20 Oppenheimer
DraftKings price target raised to $65 from $55 at Oppenheimer
DKNG DraftKings
$39.67 /

-3.05 (-7.14%)

  • 07
    Oct
  • 19
    Jun
DKNG DraftKings
$39.67 /

-3.05 (-7.14%)

DKNG DraftKings
$39.67 /

-3.05 (-7.14%)

DKNG DraftKings
$39.67 /

-3.05 (-7.14%)

Monday
Hot Stocks
Novavax down 6% to $87.41 in late afternoon trading » 15:46
10/26/20
10/26
15:46
10/26/20
15:46
NVAX

Novavax

$89.20 /

-3.88 (-4.17%)

Rumors about delays for a…

Rumors about delays for a trial of the COVID-19 vaccine being developed by Novavax have been pointed to as a possible reason for the stock's weakness, according to trading contacts.

ShowHide Related Items >><<
NVAX Novavax
$89.20 /

-3.88 (-4.17%)

NVAX Novavax
$89.20 /

-3.88 (-4.17%)

10/22/20 B. Riley Securities
Novavax price target lowered to $223 from $257 at B. Riley Securities
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/25/20 Raymond James
Endo deal could generate $50M-$75M in cash inflow, says Raymond James
09/15/20 B. Riley Securities
Novavax deal with SIIPL doubles manufacturing capacity, says B. Riley FBR
NVAX Novavax
$89.20 /

-3.88 (-4.17%)

NVAX Novavax
$89.20 /

-3.88 (-4.17%)

NVAX Novavax
$89.20 /

-3.88 (-4.17%)

NVAX Novavax
$89.20 /

-3.88 (-4.17%)

Upgrade
Apollo Global upgraded to Outperform from In Line at Evercore ISI » 06:34
10/26/20
10/26
06:34
10/26/20
06:34
APO

Apollo Global

$41.15 /

+0.475 (+1.17%)

Evercore ISI analyst…

Evercore ISI analyst Glenn Schorr upgraded Apollo Global to Outperform from In Line with a $52 price target.

ShowHide Related Items >><<
APO Apollo Global
$41.15 /

+0.475 (+1.17%)

APO Apollo Global
$41.15 /

+0.475 (+1.17%)

09/28/20 Roth Capital
Roth Capital sees currently uncaptured value for both Caesars, William Hill
07/01/20 Barclays
Apollo Global price target raised to $51 from $44 at Barclays
06/30/20
Fly Intel: Top five analyst downgrades
06/30/20 Goldman Sachs
Apollo Global downgraded to Buy from Conviction Buy at Goldman Sachs
APO Apollo Global
$41.15 /

+0.475 (+1.17%)

  • 26
    Nov
APO Apollo Global
$41.15 /

+0.475 (+1.17%)

APO Apollo Global
$41.15 /

+0.475 (+1.17%)

APO Apollo Global
$41.15 /

+0.475 (+1.17%)

Sunday
On The Fly
Bet On It: Pennsylvania a battleground state for sportsbooks » 07:05
10/25/20
10/25
07:05
10/25/20
07:05
CZR

Caesars

$54.70 /

+0.53 (+0.98%)

, LVS

Las Vegas Sands

$50.69 /

+0.87 (+1.75%)

, DKNG

DraftKings

$42.79 /

-0.25 (-0.58%)

, PDYPY

Flutter Entertainment

$0.00 /

+ (+0.00%)

, MGM

MGM Resorts

$23.37 /

+0.74 (+3.27%)

, PENN

Penn National

$62.81 /

-0.93 (-1.46%)

Welcome to The Fly's…

ShowHide Related Items >><<
PDYPY Flutter Entertainment
$0.00 /

+ (+0.00%)

MGM MGM Resorts
$23.37 /

+0.74 (+3.27%)

LVS Las Vegas Sands
$50.69 /

+0.87 (+1.75%)

DKNG DraftKings
$42.79 /

-0.25 (-0.58%)

CZR Caesars
$54.70 /

+0.53 (+0.98%)

CZR Caesars
$54.70 /

+0.53 (+0.98%)

10/16/20 Morgan Stanley
Caesars price target raised to $68 from $54 at Morgan Stanley
10/08/20 Truist
DraftKings price target raised to $60 from $39 at Truist
10/05/20 Union Gaming
Caesars price target raised to $100 from $60 at Union Gaming
10/05/20 JPMorgan
Caesars price target raised to $67 from $63 at JPMorgan
LVS Las Vegas Sands
$50.69 /

+0.87 (+1.75%)

10/22/20 JPMorgan
Las Vegas Sands price target raised to $58 from $50 at JPMorgan
10/22/20 Stifel
Las Vegas Sands price target lowered to $60 from $64 at Stifel
10/20/20 JPMorgan
Las Vegas Sands price target lowered to $50 from $57 at JPMorgan
10/20/20 Deutsche Bank
Las Vegas Sands price target lowered to $58 from $60 at Deutsche Bank
DKNG DraftKings
$42.79 /

-0.25 (-0.58%)

10/15/20 Craig-Hallum
Strong results in NJ to encourage states to legalize iGaming, says Craig-Hallum
10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Benchmark
DraftKings price target raised to $60 from $57 at Benchmark
10/12/20 Oppenheimer
DraftKings price target raised to $65 from $55 at Oppenheimer
PDYPY Flutter Entertainment
$0.00 /

+ (+0.00%)

09/22/20 Morgan Stanley
Barstool Sportsbook app 'bullish' for the sector, says Morgan Stanley
09/15/20 Oppenheimer
DraftKings price target raised to $55 from $50 at Oppenheimer
09/14/20 Deutsche Bank
Flutter price target raised to 11,800 GBp from 10,200 GBp at Deutsche Bank
09/08/20 Barclays
Flutter Entertainment upgraded to Overweight from Equal Weight at Barclays
MGM MGM Resorts
$23.37 /

+0.74 (+3.27%)

10/12/20
Fly Intel: Top five analyst downgrades
10/12/20 Barclays
MGM Resorts downgraded to Underweight from Equal Weight at Barclays
10/05/20 Roth Capital
Macau numbers likely to go lower again, says Roth Capital
09/24/20 Truist
Truist raises price targets on select Gaming names
PENN Penn National
$62.81 /

-0.93 (-1.46%)

10/19/20 Rosenblatt
Barstool started strong in PA online sports betting, says Rosenblatt
10/12/20 Barclays
Penn National price target raised to $85 from $50 at Barclays
PENN Penn National
$62.81 /

-0.93 (-1.46%)

MGM MGM Resorts
$23.37 /

+0.74 (+3.27%)

LVS Las Vegas Sands
$50.69 /

+0.87 (+1.75%)

DKNG DraftKings
$42.79 /

-0.25 (-0.58%)

CZR Caesars
$54.70 /

+0.53 (+0.98%)

  • 07
    Oct
  • 29
    Sep
  • 25
    Sep
  • 19
    Jun
  • 12
    May
DKNG DraftKings
$42.79 /

-0.25 (-0.58%)

CZR Caesars
$54.70 /

+0.53 (+0.98%)

PDYPY Flutter Entertainment
$0.00 /

+ (+0.00%)

LVS Las Vegas Sands
$50.69 /

+0.87 (+1.75%)

CZR Caesars
$54.70 /

+0.53 (+0.98%)

PENN Penn National
$62.81 /

-0.93 (-1.46%)

MGM MGM Resorts
$23.37 /

+0.74 (+3.27%)

LVS Las Vegas Sands
$50.69 /

+0.87 (+1.75%)

DKNG DraftKings
$42.79 /

-0.25 (-0.58%)

CZR Caesars
$54.70 /

+0.53 (+0.98%)

Friday
On The Fly
Friday Parlay: Pennsylvania a battleground state for sportsbooks » 16:04
10/23/20
10/23
16:04
10/23/20
16:04
CZR

Caesars

$54.66 /

+0.485 (+0.90%)

, LVS

Las Vegas Sands

$50.73 /

+0.91 (+1.83%)

, DKNG

DraftKings

$42.54 /

-0.5 (-1.16%)

, PDYPY

Flutter Entertainment

$0.00 /

+ (+0.00%)

, MGM

MGM Resorts

$23.41 /

+0.775 (+3.42%)

, PENN

Penn National

$62.78 /

-0.96 (-1.51%)

Welcome to The Fly's…

ShowHide Related Items >><<
PDYPY Flutter Entertainment
$0.00 /

+ (+0.00%)

MGM MGM Resorts
$23.41 /

+0.775 (+3.42%)

LVS Las Vegas Sands
$50.73 /

+0.91 (+1.83%)

DKNG DraftKings
$42.54 /

-0.5 (-1.16%)

CZR Caesars
$54.66 /

+0.485 (+0.90%)

CZR Caesars
$54.66 /

+0.485 (+0.90%)

10/16/20 Morgan Stanley
Caesars price target raised to $68 from $54 at Morgan Stanley
10/08/20 Truist
DraftKings price target raised to $60 from $39 at Truist
10/05/20 Union Gaming
Caesars price target raised to $100 from $60 at Union Gaming
10/05/20 JPMorgan
Caesars price target raised to $67 from $63 at JPMorgan
LVS Las Vegas Sands
$50.73 /

+0.91 (+1.83%)

10/22/20 JPMorgan
Las Vegas Sands price target raised to $58 from $50 at JPMorgan
10/22/20 Stifel
Las Vegas Sands price target lowered to $60 from $64 at Stifel
10/20/20 JPMorgan
Las Vegas Sands price target lowered to $50 from $57 at JPMorgan
10/20/20 Deutsche Bank
Las Vegas Sands price target lowered to $58 from $60 at Deutsche Bank
DKNG DraftKings
$42.54 /

-0.5 (-1.16%)

10/15/20 Craig-Hallum
Strong results in NJ to encourage states to legalize iGaming, says Craig-Hallum
10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Benchmark
DraftKings price target raised to $60 from $57 at Benchmark
10/12/20 Oppenheimer
DraftKings price target raised to $65 from $55 at Oppenheimer
PDYPY Flutter Entertainment
$0.00 /

+ (+0.00%)

09/22/20 Morgan Stanley
Barstool Sportsbook app 'bullish' for the sector, says Morgan Stanley
09/15/20 Oppenheimer
DraftKings price target raised to $55 from $50 at Oppenheimer
09/14/20 Deutsche Bank
Flutter price target raised to 11,800 GBp from 10,200 GBp at Deutsche Bank
09/08/20 Barclays
Flutter Entertainment upgraded to Overweight from Equal Weight at Barclays
MGM MGM Resorts
$23.41 /

+0.775 (+3.42%)

10/12/20
Fly Intel: Top five analyst downgrades
10/12/20 Barclays
MGM Resorts downgraded to Underweight from Equal Weight at Barclays
10/05/20 Roth Capital
Macau numbers likely to go lower again, says Roth Capital
09/24/20 Truist
Truist raises price targets on select Gaming names
PENN Penn National
$62.78 /

-0.96 (-1.51%)

10/19/20 Rosenblatt
Barstool started strong in PA online sports betting, says Rosenblatt
10/12/20 Barclays
Penn National price target raised to $85 from $50 at Barclays
PENN Penn National
$62.78 /

-0.96 (-1.51%)

MGM MGM Resorts
$23.41 /

+0.775 (+3.42%)

LVS Las Vegas Sands
$50.73 /

+0.91 (+1.83%)

DKNG DraftKings
$42.54 /

-0.5 (-1.16%)

CZR Caesars
$54.66 /

+0.485 (+0.90%)

  • 07
    Oct
  • 29
    Sep
  • 25
    Sep
  • 19
    Jun
  • 12
    May
DKNG DraftKings
$42.54 /

-0.5 (-1.16%)

CZR Caesars
$54.66 /

+0.485 (+0.90%)

PDYPY Flutter Entertainment
$0.00 /

+ (+0.00%)

LVS Las Vegas Sands
$50.73 /

+0.91 (+1.83%)

CZR Caesars
$54.66 /

+0.485 (+0.90%)

PENN Penn National
$62.78 /

-0.96 (-1.51%)

MGM MGM Resorts
$23.41 /

+0.775 (+3.42%)

LVS Las Vegas Sands
$50.73 /

+0.91 (+1.83%)

DKNG DraftKings
$42.54 /

-0.5 (-1.16%)

CZR Caesars
$54.66 /

+0.485 (+0.90%)

Periodicals
Aksia, CT treasurer halt new investments with Apollo, Bloomberg says » 14:28
10/23/20
10/23
14:28
10/23/20
14:28
APO

Apollo Global

$40.80 /

+0.13 (+0.32%)

Aksia has told its…

Aksia has told its clients to not give new money to Apollo Global Management amid lingering questions about the relationship between Apollo's co-founder Leon Black and Jeffrey Epstein, reported Bloomberg's Gillian Tan, citing an Aksia client communication. Meanwhile, Gabrielle Farrell, a spokeswoman for Connecticut's State Treasurer Shawn Wooden, said in an emailed statement to Bloomberg: "The existing Apollo commitments were made under the previous administration and we have no plans to commit further capital to their funds at this time."

ShowHide Related Items >><<
APO Apollo Global
$40.80 /

+0.13 (+0.32%)

APO Apollo Global
$40.80 /

+0.13 (+0.32%)

09/28/20 Roth Capital
Roth Capital sees currently uncaptured value for both Caesars, William Hill
07/01/20 Barclays
Apollo Global price target raised to $51 from $44 at Barclays
06/30/20
Fly Intel: Top five analyst downgrades
06/30/20 Goldman Sachs
Apollo Global downgraded to Buy from Conviction Buy at Goldman Sachs
APO Apollo Global
$40.80 /

+0.13 (+0.32%)

  • 26
    Nov
APO Apollo Global
$40.80 /

+0.13 (+0.32%)

APO Apollo Global
$40.80 /

+0.13 (+0.32%)

APO Apollo Global
$40.80 /

+0.13 (+0.32%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.